Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL).
Hun Ju Lee
No relevant relationships to disclose
William G. Wierda
No relevant relationships to disclose
Alessandra Ferrajoli
No relevant relationships to disclose
Jan Andreas Burger
No relevant relationships to disclose
Long Trinh
No relevant relationships to disclose
Susan Lerner
No relevant relationships to disclose
Michael J. Keating
No relevant relationships to disclose
Susan Mary O'Brien
Research Funding - Genentech